Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti

Share:

Listens: 0

MedEdTalks - Gastroenterology

Miscellaneous


In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.